Mark Schoenberg, Chief Medical Officer, on July 09, 2026, sold 10,000 shares in Urogen Pharma (URGN) for $400,000. Following the Form 4 filing with the SEC, Schoenberg has control over a total of 119,763 ordinary shares of the company, with 119,763 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1668243/000143774926023290/xslF345X05/rdgdoc.xml
Price: $39.70, Change: $-0.53, Percent Change: -1.32%
Briseno Andres Ruiz, Chief Accounting Officer, on July 07, 2026, sold 9,550 shares in Ideaya Biosciences (IDYA) for $382,131. Following the Form 4 filing with the SEC, Ruiz has control over a total of 26,466 common shares of the company, with 26,466 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1676725/000161071726000336/xslF345X05/form4.xml
Michael A Metzger, Director, Chief Executive Officer, on July 08, 2026, sold 32,375 shares in Syndax Pharmaceuticals (SNDX) for $784,776. Following the Form 4 filing with the SEC, Metzger has control over a total of 484,843 common shares of the company, with 484,843 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1395937/000119312526299803/xslF345X05/ownership.xml
Peter A. Thompson, Director, on July 07, 2026, sold 85,918 shares in Sionna Therapeutics (SION) for $3,854,281. Following the Form 4 filing with the SEC, Thompson has control over a total of 2,469,959 common shares of the company, with 2,469,959 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2036042/000094787126000695/xslF345X05/ownership.xml